MedTrace Logo

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-11-05

No results posted yet for this study

Summary

A prospective open label trial of adult patients with active Crohn's disease to determine if plasma concentrations of certolizumab pegol correlate to mucosal healing.

Conditions

Interventions

DRUG

Certolizumab Pegol

Subcutaneous Injection

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Shafran Gastroenterology Center

    lead OTHER

Principal Investigators

  • Ira Shafran, M.D. · Shafran Gastroenterology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-05-31
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597829 on ClinicalTrials.gov